Custom Compound Medications on Pharmacy Lien: Attorney Guide

James Wong — Founder & Pharmacist, LienScripts | March 29, 2026 | 8 min read

Custom compound medications combine multiple active ingredients into a single formulation tailored to the patient's injury profile. This guide covers medical necessity documentation, insurance barriers, adjuster challenges, and pharmacy lien coverage for compounded prescriptions in PI cases.

A custom compound medication is a prescription prepared by a compounding pharmacy that combines two or more active pharmaceutical ingredients into a single formulation tailored to an individual patient's clinical needs, and in personal injury cases, compounds represent the intersection of personalized medicine and evidence-based pain management — where a physician determines that no commercially available product adequately addresses the patient's specific injury profile. For PI attorneys, compound medications in the pharmacy record document a level of clinical customization that communicates injury severity and treatment complexity in ways that standard commercial medications cannot.

• Compounding pharmacies prepare medications by combining multiple active ingredients (e.g., ketoprofen 10% + lidocaine 5% + gabapentin 6% + cyclobenzaprine 2%) into creams, gels, or other dosage forms tailored to the patient's specific pain profile
• The FDA distinguishes between 503A compounding (patient-specific prescriptions) and 503B outsourcing facilities, with compounded PI medications falling under 503A — each preparation is made for a named patient based on a licensed prescriber's order (FDA Guidance, Compounding and the FDA)
• LienScripts operates a compounding pharmacy that prepares custom formulations on pharmacy lien and documents each compound in the POGOS (Pharmacy-Organized General Occurrence Summary) report with ingredient rationale
• According to James Wong, PharmD, founder of LienScripts, "A compound prescription tells the adjuster that no off-the-shelf medication was sufficient for this patient's injuries — the physician had to design a custom medication. That is inherently a statement about injury complexity"
• Insurance coverage for compounded medications has been restricted industry-wide since 2015, with most commercial plans excluding compounds entirely or imposing prohibitive prior authorization requirements

Why Physicians Prescribe Compounds for PI Patients

Compounding is not about creating exotic medications — it is about solving specific clinical problems that commercially available products cannot address:

Multi-Mechanism Pain

PI injuries often involve overlapping pain types at a single anatomical site: inflammatory pain (damaged tissue), neuropathic pain (nerve injury), and muscular pain (spasm). No single commercial medication addresses all three simultaneously. A compound combining an NSAID (ketoprofen), an anesthetic (lidocaine), a neuropathic agent (gabapentin), and a muscle relaxant (cyclobenzaprine) delivers targeted multi-mechanism therapy in a single application.

Topical Delivery of Oral-Only Medications

Some medications with excellent analgesic properties are only commercially available in oral form. Compounding allows these medications to be formulated as topical creams or gels, delivering the drug directly to the injury site while minimizing systemic side effects. Common examples include:

• Gabapentin topical — neuropathic pain relief without systemic sedation
• Baclofen topical — muscle spasm relief without systemic drowsiness
• Amitriptyline topical — neuropathic pain relief without systemic anticholinergic effects
• Ketamine topical — NMDA receptor antagonism for centrally sensitized pain without dissociative effects

Dose Customization

Commercial products come in fixed doses and concentrations. Compounding allows the physician to specify exact concentrations — higher for severe cases, lower for sensitive patients, adjusted based on treatment response. This dose precision is itself documentation of individualized clinical management.

Allergen and Excipient Avoidance

Some patients react to inactive ingredients (dyes, preservatives, lactose) in commercial products. Compounding allows the pharmacist to prepare the medication without the offending excipient while maintaining the active ingredient.

[!KEY] A compound prescription in the pharmacy record is a clinical statement: the physician evaluated the patient's pain condition and determined that no commercially available product was adequate. The compound was designed specifically for this patient's injury profile. This level of clinical customization is inherently evidence of treatment complexity.

Common Compound Formulations in PI Cases

Topical Pain Compounds

The most frequently prescribed compounds in PI cases are topical pain formulations:

Neuropathic pain compound: Gabapentin 6% / Lidocaine 5% / Ketoprofen 10% in PLO gel — targets nerve pain, provides local anesthesia, and reduces inflammation at the injury site.

Muscle spasm compound: Cyclobenzaprine 2% / Baclofen 2% / Lidocaine 5% in cream base — relaxes muscle spasm and provides anesthetic relief for myofascial pain.

Post-surgical compound: Ketoprofen 10% / Lidocaine 5% / Gabapentin 6% / Cyclobenzaprine 2% in Lipoderm base — comprehensive pain management at the surgical site combining anti-inflammatory, anesthetic, neuropathic, and muscle relaxant agents.

CRPS compound: Ketamine 10% / Gabapentin 6% / Clonidine 0.2% / Lidocaine 5% in PLO gel — targets the central sensitization, neuropathic pain, sympathetic dysfunction, and allodynia characteristic of complex regional pain syndrome.

Oral Compounds

Less common in PI cases but occasionally prescribed when a patient cannot tolerate a commercially available oral formulation:

• Custom-dose pain medications when the patient needs a dose between commercially available strengths
• Allergen-free formulations when the patient reacts to excipients in the commercial product
• Combination capsules reducing pill burden for patients on multiple medications

[!TIP] When reviewing compound prescriptions in the pharmacy record, note the specific ingredients and their concentrations. Each ingredient addresses a different aspect of the patient's pain condition, and the combination documents multi-mechanism pain requiring multi-target therapy. Present this in the demand package as evidence of injury complexity.

Insurance Barriers to Compound Medications

The insurance industry has systematically restricted compound medication coverage since approximately 2015:

• Blanket exclusions — many plans exclude all compounded medications from coverage
• No NDC processing — compounded medications lack National Drug Codes, and many insurance systems cannot process claims without an NDC
• Prior authorization requirements — when coverage theoretically exists, the prior authorization process for compounds is substantially more burdensome than for commercial products
• Ingredient-by-ingredient review — some insurers require separate clinical justification for each active ingredient in the compound
• Compounding pharmacy network restrictions — many plans limit coverage to specific compounding pharmacies, which may not be accessible to the patient

As Amar Lunagaria, PharmD, LienScripts' Chief Pharmacist explains, "Insurance coverage for compounds has effectively disappeared for most PI patients. The pharmacy lien is not just helpful for compound access — it is necessary. Without lien coverage, most PI patients simply cannot obtain the compound medications their physicians prescribe."

Adjuster Challenges and Attorney Responses

Challenge: "Compounds are overpriced and unnecessary"

Response: Each ingredient in the compound is a commercially available medication with established clinical evidence. The compound combines them into a single, patient-specific formulation as directed by a licensed physician. The compound is not exotic — it is a customized combination of proven medications.

Challenge: "The patient should use OTC alternatives"

Response: The prescribing physician determined that commercially available OTC products were insufficient. The compound addresses multiple pain mechanisms that no single OTC product can treat. The physician's clinical judgment — not the adjuster's cost preference — determines medical necessity.

Challenge: "Compound pharmacies charge inflated prices"

Response: Compounding requires specialized equipment, pharmacist expertise, quality-tested ingredients, and individual preparation for each prescription. The cost reflects the clinical and operational complexity of custom medication preparation. LienScripts provides transparent pricing documentation in the POGOS report.

[!KEY] Every compound prescription was ordered by a licensed physician for a specific clinical reason. The medical necessity documentation — the physician's prescription with the specified ingredients and the clinical rationale in the medical record — is the primary defense against adjuster challenges. The POGOS report from LienScripts connects each compound ingredient to the patient's diagnosed conditions.

Documentation Strategy for Demand Packages

1. Physician rationale — obtain a letter or declaration from the prescribing physician explaining why a compound was prescribed instead of commercially available alternatives
2. Ingredient analysis — present each active ingredient's clinical purpose: "Ketoprofen for inflammation, lidocaine for local pain, gabapentin for nerve damage, cyclobenzaprine for muscle spasm"
3. POGOS report — the LienScripts report documents the compound formulation, dispensing history, and clinical context
4. Treatment progression — show the progression from standard commercial medications to compounding, documenting that less complex treatments were insufficient

FAQs

Related Resources

• Ketoprofen Topical for Pain After an Injury
• Compound Medications in Personal Injury Cases
• Specialty Medications in Personal Injury
• What Is a Pharmacy Lien?